Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GD2-CAR iNK cells
- Development stage
- Preclinical
- Lead developer
- Seoul National University Hospital
- Modality
- iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies, CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intratumoral
01
Overview
GD2-CAR iNK cells are an experimental off-the-shelf cellular immunotherapy consisting of natural killer (NK) cells derived from induced pluripotent stem cells (iPSCs) and engineered to express a chimeric antigen receptor (CAR) targeting the ganglioside GD2. Developed by researchers at Seoul National University Hospital, this therapy leverages the innate cytotoxic potential of NK cells and the scalability of iPSC technology to create a standardized treatment for GD2-positive malignancies, such as glioblastoma. The CAR construct enables specific recognition and lysis of tumor cells expressing GD2, a surface antigen frequently overexpressed in neuroectodermal tumors. Preclinical studies in glioblastoma models have demonstrated significant antitumor activity and a favorable safety profile, suggesting potential as a versatile immunotherapeutic strategy.
- Other names
- GD2-specific CAR-engineered iPSC-derived NK cellsGD-2-specific CAR-engineered iPSC-derived NK cellsGD 2-specific CAR-engineered iPSC-derived NK cellsGD2-CAR-iNKGD-2-CAR-iNKGD 2-CAR-iNKGD2-CAR iPSC-derived NK cellsGD-2-CAR iPSC-derived NK cellsGD 2-CAR iPSC-derived NK cells
02
Targets
GD2
Beyond the preview
Go deeper on GD2-CAR iNK cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GD2-CAR iNK cells.